Conference Coverage

Leg lymphedema after gynecologic lymphadenectomy exceeds expectations


 

REPORTING FROM SGO 2018

– Leg lymphedema occurred in 19%-40% of women with a gynecologic cancer who underwent surgery with lymphadenectomy in a prospective study of 821 U.S. patients.

The incidence of lymphedema of the lower extremity (LLE) during 2 years of follow-up was 18% among 672 endometrial cancer patients, 25% among 124 cervical cancer patients, and 40% among 24 vulvar cancer patients, Jay W. Carlson, DO, said at the annual meeting of the Society of Gynecologic Oncology.

Although the study followed patients for 2 years after surgery, 84% of the LLE events occurred within the first 6 months after surgery, and 95% within the first 12 months. The robust incidence rates documented in this study contrasted with a general perception that LLE is relatively uncommon, leading Dr. Carlson to note that the new data show “the incidence of LLE is under recognized.” The findings also bucked conventional wisdom by showing no link between the incidence of LLE and number of lymph nodes dissected or with use of radiation treatment, said Dr. Carlson, a gynecologic oncologist at Mercy Clinic Women’s Oncology in Springfield, Mo.

To better define the incidence of LLE after lymphadenectomy for gynecologic cancers, the Gynecologic Oncology Group organized the Lymphedema and Gynecologic Cancer (LEG) study, run at more than 70 U.S. centers during June 2012–November 2014. The study enrolled patients scheduled for surgery to treat endometrial, cervical, or vulvar cancer, and applied systematic leg measurement to patients just before and at several prespecified times following surgery through 2 years of follow-up.

The study began with a total of 1,054 patients, but the final analysis that Dr. Carlson presented excluded patients who did not actually undergo lymphadenectomy during their surgery, did not have leg volume data available both before and after their surgery, or had a comorbidity or change in body mass that could have caused the change in leg size. The researchers also required patients identified with LLE to have completed the Gynecologic Cancer Lymphedema Questionnaire (Gynecol Oncol. 2010 May;117[2]:317-23) and tallied a score of at least 4, and to have at least a 10% increase in leg volume at the time of diagnosis, compared with the presurgical volume.

The exclusions yielded a total of 672 patients with endometrial cancer, including 127 who developed LLE (19%); 124 patients with cervical cancer, including 31 who developed LLE (25%); and 25 patients with vulvar cancer, including 10 who developed LLE (40%), Dr. Carlson reported.

Analysis of the patients who developed LLE showed no significant association with type of surgery (open, robotic, or laparoscopic), and no significant associations with several patient-specific factors including age, race, cancer stage, surgical blood loss, or serum albumin, he said.

On Twitter @mitchelzoler

SOURCE: Carlson J et al. SGO 2018, Abstract 11.

Recommended Reading

Fibroids associated with lower chance of unsuspected malignancy
MDedge Surgery
FDA: Laparoscopic power morcellators can spread malignant cells when used in women with occult uterine cancers*
MDedge Surgery
Age at RRSO affects peritoneal cancer risk in BRCA mutation carriers
MDedge Surgery
HIPEC shows survival benefit for advanced ovarian cancer
MDedge Surgery
Same-day discharge for hysterectomy
MDedge Surgery
Study: No increased risk of serious AEs with combined urogyn/gyn onc surgery
MDedge Surgery
VIDEO: Cervical cancer laparotomy outperforms minimally invasive surgery
MDedge Surgery
VIDEO: Interventions target opioid overprescribing after gynecologic surgery
MDedge Surgery
Residual single-site ovarian cancer surpasses multisite outcomes
MDedge Surgery
What is HIPEC?
MDedge Surgery